The U.S. Food and Drug Administration accepted Priovant Therapeutics’ New Drug Application for brepocitinib and granted the drug Priority Review on March 3 2026, setting a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of 2026.
The decision follows the Phase 3 VALOR study, which enrolled 241 patients and demonstrated that brepocitinib 30 mg met the primary endpoint and nine key secondary endpoints. 62 % of patients on brepocitinib achieved a steroid dose of ≤2.5 mg/day by study end, and 42 % discontinued steroids entirely, compared with 34 % and 23 % in the placebo group. Serious infections were more common at the 30 mg dose, but the overall safety profile was comparable to other TYK2/JAK1 inhibitors in the class.
Brepocitinib is an oral dual selective inhibitor of TYK2 and JAK1, targeting cytokine pathways that drive inflammation in dermatomyositis. If approved, it would be the first targeted therapy and the first oral therapy for this rare autoimmune disease, potentially replacing high‑dose systemic steroids that carry significant long‑term risks.
The FDA’s acceptance and Priority Review designation mean the agency will aim to complete its review within six months, positioning a U.S. launch for the end of September 2026. The milestone is expected to reshape the treatment landscape for dermatomyositis, a disease with limited options and a high unmet need, and to provide a new, steroid‑sparing therapeutic option for patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.